A novel small-molecule inhibitor of androgen receptor (AR) N-terminal domain inhibitor for the treatment of advanced prostate cancer.

A novel small-molecule inhibitor of androgen receptor (AR) N-terminal domain inhibitor for the treatment of advanced prostate cancer.

A potent nuclear receptor TR3 (Nur77)-specific targeting compound that can induce melanoma autophagy through a mitochondrial signaling pathway.

GNF-351 is a potent, pure aryl hydrocarbon receptor (AHR) antagonist (IC50=62 nM) devoid of partial agonist potential; antagonizes agonist and SAhRM-mediated suppression of SAA1, inhibit both DRE-dependent and -independent activity; decreases migration and invasion of HNSCC cells and prevents benzo[a]pyrene-mediated induction of the chemotherapy efflux protein ABCG2.

A potent, selective, CNS penetrant, orally bioavailable RORγt with pIC50 of 8.3 in FRET assays.

A potent, subtype-selective, orally available eIF4A3 inhibitor with IC50 of 0.14 uM.

A retinoic acid analog and selective RARα agonist

A rocaglate (flavagline) derivative that acts a highly specific inhibitor of the oncogenic translation program supporting MM, including key oncoproteins such as MYC, MDM2, CCND1, MAF, and MCL-1.

A small molecule, selective FOXO1 inhibitor that inhibits FOXO-dependent glucose production devoid of lipogenic activity in hepatocytes.

A synthetic glucocorticoid corticosteroid..

A synthetic, steroidal progesterone receptor (PR) antagonist with reduced antiglucocorticoid activity compared to mifepristone..

A-484954 is a highly selective eukaryotic elongationfactor-2 (eEF2) inhibitor, with an IC50 of 280 nM.

AC261066 (AC-261066, AC261) is a potent, selective, orally available RARβ2 agonist with pEC50 of 8.1, displays selectivity over RARβ1, RARα and RARγ (pEC50=6.4, 6.2 and 6.3).

acolbifene, also known as EM-652, or SCH-57068, is a selective estrogen receptor modulator (SERM). Acolbifene is currently being studied in the prevention of breast cancer in women at high risk of breast cancer. EM-652 (SCH 57068) and the prodrug EM-800 (

ACP-105 is a novel non-steroidal SARM (Selective Androgen Receptor Modulator).

Andarine (S-4) is an investigational selective androgen receptor modulator (SARM) and an active partial agonist.

APTO-253 is a novel small molecule with potent anti-tumor activity in cancer cells via induction of the gene that expresses the Krüppel-like factor 4 (KLF4) master transcription factor, leading to cell cycle inhibition and programmed cell death.

APY29 is an allosteric modulator of IRE1α; inhibits IRE1α autophosphorylation (IC50 = 280 nM) and activates IRE1α RNase activity.

AR7 is a retinoic acid receptor α (RARα) antagonist.

ARN-509 is a selective and competitive androgen receptor inhibitor with IC50 of 16 nM, useful for prostate cancer treatment.

AS1842856 is a potent and cell-permeable Foxo1 inhibitor with an IC50 of 30 nM.

ASC-J9, is antitumor agent. ASC-J9 suppresses castration-resistant prostate cancer growth via degradation of full-length and splice variant androgen receptors.